Welcome to our dedicated page for IMRA news (Ticker: IMRA), a resource for investors and traders seeking the latest updates and insights on IMRA stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect IMRA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of IMRA's position in the market.
Imara Inc. (Nasdaq: IMRA) will host a conference call on August 6, 2021, at 8:30 a.m. ET to discuss its Q2 2021 financial results and recent business updates. The call can be accessed domestically at 1 (833) 519-1307 or internationally at +1 (914) 800-3873 with conference ID 6499377. Imara is focused on developing IMR-687, a potential treatment for sickle cell disease and beta-thalassemia. The drug is a selective inhibitor of PDE9 and aims to provide a multimodal mechanism of action, improving patient outcomes.
Imara Inc. (Nasdaq: IMRA) announced its public offering of shares at $6.00 each, raising gross proceeds of $50 million before expenses. The offering, expected to close on July 16, 2021, will allow the company to further develop its therapeutics for rare genetic disorders. Underwriters have a 30-day option to purchase an additional $7.5 million in shares. The shares are being offered under a previously filed shelf registration statement with the SEC.
Imara Inc. (Nasdaq: IMRA) announced a proposed underwritten public offering of $50 million of common stock, all offered by the Company. The offering is subject to market conditions, with a potential additional $7.5 million option for underwriters. This move follows a shelf registration statement filed on April 1, 2021. Imara is focused on developing therapies for rare genetic hemoglobin disorders, including its lead drug candidate, IMR-687, for sickle cell disease and beta-thalassemia. The timing and terms of the offering remain uncertain.
Imara Inc. has elected Dr. Laura A. Williams to its Board of Directors, bringing over 25 years of drug development and patient advocacy experience. Dr. Williams, currently the Senior VP at Ardelyx, is noted for her leadership in clinical trials and commitment to patient needs. Her expertise is expected to greatly aid Imara in advancing its lead therapeutic, IMR-687, for treating sickle cell disease and beta-thalassemia. The announcement follows the departure of Mette Kirstine Agger from the Board after five years.
Imara has expanded its Real Impact community support initiative, awarding 30 grants totaling $150,000 to nonprofit organizations assisting patients with sickle cell disease and beta-thalassemia. This year’s funding increased by $25,000 from 2020. The grants, assessed by external reviewers, will impact 16 states and focus on social determinants of health, virtual programming, and capacity enhancement for organizations. The initiative aims to improve the lives of affected individuals and their families by supporting local community organizations.
Imara Inc. announced positive final findings from its 93-patient Phase 2a clinical trial of IMR-687 for sickle cell disease (SCD), showing a 40% reduction in annualized vaso-occlusive crises (VOCs) compared to placebo. The study highlighted a significant increase in the time to first VOC (169 days vs 87 days) and improved patient-reported pain severity. Interim data from the open-label extension trial demonstrated sustained lower VOC rates and increased fetal hemoglobin (HbF) responses over eight months. IMR-687 was well-tolerated, paving the way for further trials, including the ongoing Ardent Phase 2b.
Imara Inc. (Nasdaq: IMRA) announces the presentation of final results from its 93-patient Phase 2a trial and interim data from the open-label extension trial for IMR-687, aimed at treating sickle cell disease. The results will be shared at the EHA Annual Congress from June 9-17, 2021. IMR-687 was shown to be well tolerated, with promising reductions in vaso-occlusive crises rates and increases in fetal hemoglobin levels. A conference call is scheduled for June 11, 2021, to discuss the findings further.
Imara Inc. (Nasdaq: IMRA) reported Q1 2021 financial results and highlighted progress in clinical trials for sickle cell disease and beta-thalassemia. The company completed enrollment for the transfusion-dependent arm of the Forte Phase 2b trial and opened higher dose arms for both Ardent and Forte trials. Cash reserves stand at $75.6 million. Q1 net loss was $10.3 million, down from $15.1 million a year ago. The firm expects R&D expenses between $50 million and $55 million for 2021. Interim analyses for the clinical trials are anticipated in H2 2021.
Imara Inc. (Nasdaq: IMRA) will host a conference call on May 11, 2021, at 8:30 a.m. ET to discuss its Q1 2021 financial results and recent business highlights. The call will be accessible through a live webcast on the company’s website. Imara is focused on developing therapies for rare genetic disorders affecting hemoglobin, with its lead candidate, IMR-687, targeting conditions such as sickle cell disease and beta-thalassemia. IMR-687 is a potent oral treatment designed to modify disease mechanisms.
FAQ
What is the market cap of IMRA (IMRA)?
